Key insights from lung cancer research at ASCO 2025
Dr Antonio Passaro (European Institute of Oncology, Milan, Italy), Dr Umberto Malapelle (University of Naples Federico II, Naples, Italy) and Dr Joshua Sabari (NYU Langone Health, New York City, USA) discuss EGFR testing and the best practice for patients with Exon 20 insertions.
Initially, they discuss some treatment options for Exon 20 insertion mutation NSCLC patients. Dr Malapelle and Dr Passaro then talk about the different methodologies for EGFR Exon 20 insertions testing.
Dr Malapelle mentions which of these methodologies are the best to use and when to use liquid vs tissue biopsies. Dr Sabari talks about the recent research from ELCC that highlights the best treatment options for these patients.
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer